GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ligand Pharmaceuticals Inc (STU:LGDN) » Definitions » Cyclically Adjusted PB Ratio

Ligand Pharmaceuticals (STU:LGDN) Cyclically Adjusted PB Ratio : 2.32 (As of Jun. 19, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Ligand Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-06-19), Ligand Pharmaceuticals's current share price is €75.00. Ligand Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €32.28. Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 2.32.

The historical rank and industry rank for Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:LGDN' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.46   Med: 4.94   Max: 563.39
Current: 2.22

During the past years, Ligand Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 563.39. The lowest was 1.46. And the median was 4.94.

STU:LGDN's Cyclically Adjusted PB Ratio is ranked worse than
58.36% of 658 companies
in the Biotechnology industry
Industry Median: 1.665 vs STU:LGDN: 2.22

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Ligand Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2024 was €41.397. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €32.28 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Ligand Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ligand Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Ligand Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.82 3.44 4.00 2.23 2.06

Ligand Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.34 2.21 1.77 2.06 2.01

Competitive Comparison of Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Ligand Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=75.00/32.28
=2.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ligand Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Ligand Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=41.397/131.7762*131.7762
=41.397

Current CPI (Mar. 2024) = 131.7762.

Ligand Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 2.273 100.560 2.979
201409 1.712 100.428 2.246
201412 1.090 99.070 1.450
201503 1.652 99.621 2.185
201506 3.102 100.684 4.060
201509 13.070 100.392 17.156
201512 12.743 99.792 16.827
201603 16.914 100.470 22.184
201606 16.727 101.688 21.676
201609 15.791 101.861 20.429
201612 16.814 101.863 21.752
201703 17.758 102.862 22.750
201706 17.310 103.349 22.071
201709 16.894 104.136 21.378
201712 16.727 104.011 21.192
201803 18.928 105.290 23.690
201806 25.151 106.317 31.174
201809 28.418 106.507 35.160
201812 23.743 105.998 29.517
201903 48.605 107.251 59.720
201906 47.534 108.070 57.961
201909 43.975 108.329 53.493
201912 41.046 108.420 49.888
202003 37.322 108.902 45.161
202006 38.402 108.767 46.526
202009 36.819 109.815 44.182
202012 36.271 109.897 43.492
202103 37.623 111.754 44.363
202106 39.147 114.631 45.002
202109 41.315 115.734 47.042
202112 43.343 117.630 48.556
202203 42.715 121.301 46.404
202206 44.961 125.017 47.392
202209 48.802 125.227 51.354
202212 33.274 125.222 35.016
202303 35.232 127.348 36.457
202306 35.367 128.729 36.204
202309 35.923 129.860 36.453
202312 36.611 129.419 37.278
202403 41.397 131.776 41.397

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ligand Pharmaceuticals  (STU:LGDN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Ligand Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ligand Pharmaceuticals (STU:LGDN) Business Description

Traded in Other Exchanges
Address
3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA, USA, 92121
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Ligand Pharmaceuticals (STU:LGDN) Headlines

No Headlines